Search results
Results from the WOW.Com Content Network
Patients who harbor an EGFR mutation have a 60% response rate to erlotinib. However, the mutation of KRAS and EGFR are generally mutually exclusive. [29] [30] [31] Lung cancer patients who are positive for KRAS mutation (and the EGFR status would be wild type) have a low response rate to erlotinib or gefitinib estimated at 5% or less. [29]
mRNA-5671 also known as V941 is a cancer vaccine candidate developed by Moderna. [1] It is a tetravalent vaccine that targets G12D, G12V, G13D or G12C driver mutations in the KRAS gene. [ 2 ] It is currently being evaluated for the treatment of either non-small cell lung cancer , colorectal cancers with microsatellite instability , or ...
Selumetinib, had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, [5] and is now in phase III development in KRAS mutation positive NSCLC (SELECT-1, NCT01933932). Other ph 3 clinical trials underway include uveal melanoma (failed), and differentiated thyroid carcinoma.
HCT116 cells have a mutation in codon 13 of the KRAS proto-oncogene, and are suitable transfection targets for gene therapy research. [2] The cells have an epithelial morphology and can metastasize in xenograft models. [1] When transducted with viral vectors carrying the p53 gene, HCT116 cells remain arrested in the G1 phase. [3]
The signs and symptoms of colorectal cancer depend on the location of the tumor in the bowel, and whether it has spread elsewhere in the body ().The classic warning signs include: worsening constipation, blood in the stool, decrease in stool caliber (thickness), loss of appetite, loss of weight, and nausea or vomiting in someone over 50 years old. [15]
Accordingly, genetic testing to confirm the absence of KRAS mutations (and so the presence of the KRAS wild-type gene), is now clinically routine before the start of treatment with EGFR inhibitors. mCRC patients with wild-type KRAS tumors have been shown to benefit from a response rate of over 60% and a decreased risk for progression of over 40 ...
Colon cancer is the second-leading cause of cancer deaths in the United States and is expected to kill more than 53,000 people in the nation in 2024, according to the American Cancer Society.
There were 3 arms involved in this trial; MM-151 dose escalation, MM-151 expansion in KRAS wild type colorectal cancer, and MM-151 + irinotecan. [4] Merrimack Pharmaceuticals released preliminary results from trial NCT01520389 in June 2014 after presenting at the annual conference for the American Society of Cancer Oncology (ASCO).